Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00 at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) had its price target lifted by equities researchers at Stifel Nicolaus from $45.00 to $55.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 10.71% from the stock’s current price.

Other research analysts also recently issued reports about the stock. SVB Leerink raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $50.00 target price (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd. Barclays raised their price objective on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, Citigroup raised Tandem Diabetes Care from a “neutral” rating to a “buy” rating and increased their target price for the stock from $40.00 to $57.00 in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average price target of $49.73.

View Our Latest Report on Tandem Diabetes Care

Tandem Diabetes Care Trading Down 3.3 %

NASDAQ:TNDM opened at $49.68 on Wednesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $52.51. The stock has a market cap of $3.21 billion, a P/E ratio of -22.89 and a beta of 1.10. The stock has a 50-day simple moving average of $36.78 and a 200-day simple moving average of $28.66.

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical device company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.17. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The firm had revenue of $191.67 million for the quarter, compared to the consensus estimate of $173.06 million. As a group, analysts anticipate that Tandem Diabetes Care will post -1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Kingdon Capital Management L.L.C. boosted its position in Tandem Diabetes Care by 153.9% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 493,080 shares of the medical device company’s stock worth $17,460,000 after purchasing an additional 298,880 shares during the period. Silvercrest Asset Management Group LLC grew its stake in shares of Tandem Diabetes Care by 4.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 266,158 shares of the medical device company’s stock valued at $9,425,000 after buying an additional 10,907 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of Tandem Diabetes Care by 31.9% during the 1st quarter. First Light Asset Management LLC now owns 475,077 shares of the medical device company’s stock valued at $16,822,000 after buying an additional 114,834 shares during the period. Bellevue Group AG lifted its position in Tandem Diabetes Care by 2.0% during the 1st quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock worth $71,949,000 after acquiring an additional 39,571 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Tandem Diabetes Care by 5.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after acquiring an additional 1,985 shares during the period.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Further Reading

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.